bevacizumab + platinum-based chemotherapy

Bevacizumab + platinum-based chemotherapy is a combination regimen used primarily for the treatment of various advanced cancers, especially ovarian cancer. **Bevacizumab** is a recombinant humanized monoclonal antibody targeting *vascular endothelial growth factor A (VEGF-A)*, thereby inhibiting angiogenesis essential for tumor growth and survival. **Platinum-based chemotherapy** commonly refers to chemotherapeutic agents containing platinum, such as carboplatin, cisplatin, and oxaliplatin, which induce DNA crosslinking and prevent DNA replication, leading to cancer cell death. This combination therapy is FDA-approved as first-line and recurrent therapy in epithelial ovarian cancer and is also indicated in advanced non-squamous non-small cell lung cancer, metastatic colorectal cancer, cervical cancer, and other solid tumors. The addition of bevacizumab to platinum-based chemotherapy improves *progression-free survival* in several cancers, although the effect on *overall survival* is less consistent. Common adverse effects include hypertension, proteinuria, and thromboembolic events, but these are generally manageable[1][2][3][4][5][6][8].

Other names

bevacizumab + platinum-based chemotherapybevacizumab plus platinum-based chemotherapybevacizumab/chemotherapy combinations